Looking for Microplastics in the Livers of People With Cirrhosis
Checks tissue for microplastics in adults with cirrhosis and in those without liver disease.
Plain-language title generated from the registry record
Registry title: Microplastics, Cirrhosis and Portal Hypertension
Key facts
- Where
- Chandigarh, IndiaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 70 with cirrhosis who are having planned surgery or a liver transplant. Researchers will look for microplastics in their tissue.
- Age
- 18 to 70 years
- Sex
- Women and men can both join.
- Disease stage
- Cirrhosis, confirmed by tissue examination or by clinical, lab and ultrasound findings.
- Earlier treatment
- People who had earlier liver treatments such as locoregional therapy, or earlier abdominal surgery, cannot join.
Main reasons for not taking part
- Hepatocellular carcinoma (liver cancer)
- Pregnancy or breastfeeding
- HIV or antiretroviral treatment
- Earlier liver procedures such as locoregional therapy
- Earlier abdominal surgery
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07280390, who can take part
Where in India
- Dr. Madhumita PremkumarChandigarh, IndiaContact: Dr. Madhumita Premkumar, MDTaking people
- PGIMER ChandigarhChandigarh, IndiaContact: Prerna PremkumarTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Trial code
- NCT07280390
- Record updated
- 15 May 2026
- Original description
Cirrhosis and portal hypertension are associated with an hyperdynamic circulation and hepatic inflammation, leading to complications like ascites, variceal bleeding, acute kidney injury, and higher infection risk. Microplastics (MPs) are a global plastic pollution issue, and studies have found plastic MPs or nanoparticles (NPs) contaminating human, animal and environmental ecosystems.It has been noted that the accumulation of MPs increases with a reduction in size of the plastic particle. MPs are categorized into primary particles such as manufactured plastics including pellets and cosmetic microbeads and secondary particles which originate from mechanical and ultraviolet disruption of large plastic particles. MPs can be ingested via food or beverages, especially plastic packaged comestibles or inhaled as environmental pollutants. Contamination of medications such as antibiotics, intravenous fluids, albumin and medical devices is another source of exposure to microplastics in patients with chronic liver disease (CLD)In particular exposure to endoscopic interventions, liver biopsy, and invasive procedures such as paracentesis and interventional radiology procedures can lead to plastic exposure and deposition of MPs in the liver and other tissues in patients with cirrhosis. It may be hypothesized that these may contribute to hepatic inflammation and progression of cirrhosis and portal hypertension.Read full original descriptionShow less
The Impact of Microplastics and Nanoplastics on Liver Health and Cardiovascular Diseases in India
Cirrhosis and portal hypertension are associated with an hyperdynamic circulation and hepatic inflammation, leading to complications like ascites, variceal bleeding, acute kidney injury, and higher infection risk. Microplastics (MPs) are a global plastic pollution issue, and studies have found plastic MPs or nanoparticles (NPs) contaminating human, animal and environmental ecosystems.It has been noted that the accumulation of MPs increases with a reduction in size of the plastic particle. MPs are categorized into primary particles such as manufactured plastics including pellets and cosmetic microbeads and secondary particles which originate from mechanical and ultraviolet disruption of large plastic particles. MPs can be ingested via food or beverages, especially plastic packaged comestibles or inhaled as environmental pollutants. Contamination of medications such as antibiotics, intravenous fluids, albumin and medical devices is another source of exposure to microplastics in patients with chronic liver disease (CLD)In particular exposure to endoscopic interventions, liver biopsy, and invasive procedures such as paracentesis and interventional radiology procedures can lead to plastic exposure and deposition of MPs in the liver and other tissues in patients with cirrhosis. It may be hypothesized that these may contribute to hepatic inflammation and progression of cirrhosis and portal hypertension.
Globally, there is new research on the influence of MPs on the environment, plant and animal ecosystems and human health.
Polystyrene (PS) microspheres that concentrate in the liver, intestine and the kidneys of mammals disrupt lipid and energy metabolism, impair mucus secretion, and alter the microbiome. Therefore, studies are required to assess how and to what extent, MPs impact human health, and affect chronic diseases like cirrhosis and reduce longevity.
The study investigators will assess the presence of MPs in the liver, kidneys and intestine of patients with liver cirrhosis and compare it with those without underlying liver disease and determine the impact on portal hypertension and fibrosis, and cardiovascular and metabolic function.
Inclusion: Age range of 18-70 years; Cirrhosis, as diagnosed by histology or clinical, laboratory and USG findings; Undergoing elective surgery or liver transplantation.
Exclusion: • Hepatocellular carcinoma; Pregnancy or lactation; Patients with HIV or retroviral therapy; Prior liver interventions like locoregional therapy, presence of HCC, prior abdominal surgery.